Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Third Harmonic Bio (NASDAQ:THRD) shareholders have done very well over the last year, with the share ...
THIRD HARMONIC BIO ($THRD) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.35 per share, missing estimates of -$0.30 by ...
Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps THB335 Phase 1 Clinical Results The Phase 1 SAD (n=48 ...
Third Harmonic Bio's board approves and adopts a plan for the liquidation and dissolution of the company. The company estimates total shareholder distributions in the range of $246.6 million to $259.8 ...
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback